TrialAlzheimer's research & therapy2021

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.

Niels D Prins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.